8/13/2019 | CV | Ironwood greenshoes up five-, seven-year convertibles to $400 million
|
8/9/2019 | CV | Market Commentary: Convertibles issuance tops $3 billion for week, Clovis, BlackLine expand; Ironwood drops
|
8/8/2019 | CV | Market Commentary: BlackLine eyed; Alteryx, Mesa Labs expand on debut; Ironwood, CorEnergy, Clovis price
|
8/8/2019 | CV | Market Commentary: Morning Commentary: BlackLine, Clovis Oncology convertibles on tap; four deals price
|
8/8/2019 | CV | New Issue: Ironwood sells upsized $350 million five-, seven-year convertibles
|
8/7/2019 | CV | Market Commentary: Alteryx, Ironwood, Mesa Labs eyed; CorEnergy, BlackLine, Clovis on tap; Snap skyrockets
|
8/7/2019 | CV | Market Commentary: Morning Commentary: Snap skyrockets; Alteryx, Ironwood, Mesa Labs eyed; CorEnergy on tap
|
8/6/2019 | CV | Market Commentary: Alteryx, Ironwood, Mesa Lab on tap; Snap looks cheap; Chesapeake Energy, Whiting active
|
8/6/2019 | CV | Ironwood offers $330 million two-tranche convertible notes offering
|
4/16/2019 | CV | Ironwood adjusts conversion rate of 2.25% convertible notes
|
4/2/2019 | CV | Ironwood plans to adjust conversion rate of 2.25% convertible notes
|
7/9/2018 | CV | Market Commentary: Palo Alto Networks to sell $1.5 billion convertible; Teva active; Ironwood a concern
|
7/9/2018 | CV | Market Commentary: Morning Commentary: Palo Alto Networks to sell $1.5 billion convertible; Ironwood active
|
5/2/2018 | CV | Market Commentary: Five9, Teladoc on tap; JPMorgan/Voya notes, IAC convertibles active; Ironwood eyed
|
4/10/2018 | CV | Market Commentary: Convertibles secondary market firms; new paper slow to trade; Transocean in focus
|
4/6/2016 | CV | Market Commentary: Anacor rises amid speculation it’s a target; other health care names better to buy
|
2/5/2016 | CV | Market Commentary: Hess mandatory trades around par; LinkedIn falls but not as badly as shares; Workday drops
|
1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
6/30/2015 | CV | Market Commentary: Convertibles lower with month-end in focus; Impax slips below par; June primary falters
|
6/25/2015 | CV | Ironwood greenshoe lifts seven-year convertible sale to $337.5 million
|
6/17/2015 | CV | Market Commentary: Qihoo higher on going-private proposal; Ctrip.com launches $1 billion deal; Synergy spikes
|
6/11/2015 | CV | Market Commentary: New Proofpoint looks somewhat cheap; existing Proofpoint comes in small; Ironwood lingers
|
6/10/2015 | CV | Market Commentary: New Ironwood adds on swap; Avid ‘comes in’ a bit; Proofpoint launches $150 million deal
|
6/10/2015 | CV | Market Commentary: Morning Commentary: New Ironwood adds a point on swap; new Avid issue ‘comes in’ a bit
|
6/10/2015 | CV | New Issue: Ironwood Pharmaceuticals prices $300 million seven-year convertibles at 2.25%, up 35%
|
6/9/2015 | CV | Market Commentary: Planned Ironwood looks cheap; Avid pricing also looks fairly cheap; Micron notes improve
|
6/9/2015 | CV | Market Commentary: Morning Commentary: Planned Ironwood pricing looks good; Avid also in the market; Newmont trades
|
6/8/2015 | CV | Market Commentary: Convertibles quiet; Ironwood Pharmaceuticals, Avid launch deals; Tesla paper unchanged
|
6/8/2015 | CV | Ironwood Pharmaceuticals plans $300 million seven-year convertibles to yield 2.5%-3%, up 30%-35%
|